Allarity Therapeutics(ALLR) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding, - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equi ...